secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2023-10-11T23:59:59+00:00
Accession:  0001104659-23-108591
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock advances SRK-439 for obesity towards 2025 IND; Phase 2 apitegromab trial in 2024 with mid-2025 data
--------------------------------------------------------------------------------

- Plans to file IND for SRK-439, a novel myostatin inhibitor for obesity, in 2025.
- Initiating Phase 2 proof-of-concept trial of apitegromab in combination with GLP-1 RA in obesity in 2024; data expected mid-2025.
- Preclinical data show SRK-439 combined with GLP-1 RA reversed lean mass loss and enhanced fat mass loss in diet-induced obese mice.
- Pivotal Phase 3 SAPPHIRE trial of apitegromab in SMA fully enrolled; topline data expected Q4 2024.
- Leverages selective myostatin inhibition platform; apitegromab already well-tolerated in SMA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000110465923108591/0001104659-23-108591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000110465923108591/tm2328106d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-108591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer